Aclaris Therapeutics Stock Fair Value – ACLARIS THERAPEUTICS Reports Decrease of 51.2% in Q3 FY2023 Revenue

November 21, 2023

🌥️Earnings Overview

On November 6 2023, ACLARIS THERAPEUTICS ($NASDAQ:ACRS) released their FY2023 Q3 earnings results, showing a revenue decrease of 51.2% to USD 9.3 million compared to the same period in the prior year. Net income also dropped from -20.0 million to -29.3 million.

Analysis – Aclaris Therapeutics Stock Fair Value

GoodWhale conducted an analysis to evaluate ACLARIS THERAPEUTICS‘s wellbeing. Their proprietary Valuation Line revealed the intrinsic value of ACLARIS THERAPEUTICS’s share to be around $26.6. However, at present, ACLARIS THERAPEUTICS stock is being traded at a much lower price, at $5.5, which amounts to a staggering 79.3% undervaluation. This presents an opportunity for investors looking for discounted stocks with potential for growth. More…

  • Star Chart Analysis
  • Valuation Analysis
  • About the Company

  • Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Aclaris Therapeutics. More…

    Total Revenues Net Income Net Margin
    21.43 -114.62 -498.4%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Aclaris Therapeutics. More…

    Operations Investing Financing
    -90.68 41.37 26.69
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Aclaris Therapeutics. More…

    Total Assets Total Liabilities Book Value Per Share
    218.35 62.02 2.21
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Aclaris Therapeutics are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    52.9% -534.6%
    FCF Margin ROE ROA
    -427.6% -42.6% -32.8%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items

  • Peers

    It is one of many companies operating in the field, including Guardant Health Inc, Joinn Laboratories (China) Co Ltd, and Burning Rock Biotech Ltd. All of these companies are working to bring innovative treatments for skin and hair disorders to the market.

    – Guardant Health Inc ($NASDAQ:GH)

    Guardant Health Inc is a precision oncology company that develops and commercializes non-invasive tests for advanced cancer. The company has a market capitalization of 2.86 billion dollars as of 2022. Guardant Health Inc has a negative Return on Equity of -150.22%, which suggests that its current shareholders are not being rewarded for their investments. This low return is likely due to the company’s high spending on research and development in order to stay competitive in the rapidly evolving field of precision oncology.

    – Joinn Laboratories (China) Co Ltd ($SHSE:603127)

    Joinn Laboratories (China) Co Ltd is a leading global biotechnology company that develops, manufactures, and markets innovative products for the health and wellness industry. With a market capitalization of 27.83B as of 2022, Joinn Laboratories has been able to deliver strong returns on equity of 9.11%. This company has become a leader in the biotech industry due to its commitment to research and development, and its ability to stay ahead of the competition. Joinn Laboratories is focused on improving the quality of life for its customers through its cutting-edge products and services.

    – Burning Rock Biotech Ltd ($NASDAQ:BNR)

    Burning Rock Biotech Ltd is a Chinese biotechnology company focused on the development of cancer diagnostics and precision medicine. The company has a market cap of 219.91M as of 2022, indicating that it is a large and well-established company. Its Return on Equity of -46.46% indicates that the company is currently experiencing financial difficulty. This could be due to the high costs associated with developing diagnostic and precision medicine technologies, which may eventually lead to greater returns in the future.


    ACLARIS THERAPEUTICS has released its FY2023 Q3 earnings results, revealing total revenue of USD 9.3 million, a decrease of 51.2% compared to the same period last year. Net income was reported at USD -29.3 million, down from -20.0 million in the same quarter of the previous year. Investors may be deterred by the poor results, but may be encouraged by the company’s focus on reducing costs and potential for future growth. The stock could be a good buy for risk-seeking investors who have an appetite for potential rewards.

    Recent Posts

    Leave a Comment